期刊
CURRENT ONCOLOGY REPORTS
卷 17, 期 10, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-015-0468-7
关键词
mCRPC; CSPC; Taxanes; Docetaxel; Cabazitaxel; Mitoxantrone; Taxotere; Jevtana; Novantrone; Chemohormonal; Prostate; Neuroendocrine; Small cell; Adenocarcinoma; Microtubules; PSA
类别
For approximately a decade, chemotherapy has been shown to prolong life in patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time, however, only two agents have proven to prolong life (docetaxel and cabazitaxel). However, in the last year, the addition of chemotherapy to primary hormonal therapy became a standard of care for high-volume castration-sensitive metastatic disease. Here I will review current prostate cancer chemotherapies, mechanisms of resistance to those therapies, and ongoing clinical studies of chemotherapy combinations and novel chemotherapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据